Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy

Parkinsonism and Related Disorders

Volumn 17, Issue 3, 2011, Pages 160-165

  Claassen, Daniel O ^b   Lowe, Val J ^a   Peller, Patrick J ^a   Petersen, Ronald C ^a   Josephs, Keith A ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Autonomic diseases; Dementia with Lewy bodies; Multiple system atrophy; Parasomnias; PIB PET

Indexed keywords

AMYLOID; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DYSAUTONOMIA; FEMALE; GLUCOSE METABOLISM; HUMAN; LEWY BODY; MALE; OCCIPITAL LOBE; PARIETAL LOBE; PARKINSON DISEASE; PARKINSONISM; POLYSOMNOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; SHY DRAGER SYNDROME; STRIATE CORTEX; TEMPORAL LOBE;

AGED; AMYLOID; ANILINE COMPOUNDS; BRAIN MAPPING; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79951553759     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2010.12.006     Document Type: Article

References (30)

1. Gilman S., Wenning G.K., Low P.A., Brooks D.J., Mathias C.J., Trojanowski J.Q., et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008 Aug 26, 71(9):670-676.
2. Fujishiro H., Ferman T.J., Boeve B.F., Smith G.E., Graff-Radford N.R., Uitti R.J., et al. Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol 2008 Jul, 67(7):649-656.
3. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005 Dec 27, 65(12):1863-1872.
4. Papp M.I., Kahn J.E., Lantos P.L. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989 Dec, 94(1-3):79-100.
5. Jellinger K.A. More frequent Lewy bodies but less frequent Alzheimer-type lesions in multiple system atrophy as compared to age-matched control brains. Acta Neuropathol 2007 Sep, 114(3):299-303.
6. Wenning G.K., Ben Shlomo Y., Magalhaes M., Daniel S.E., Quinn N.P. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994 Aug, 117(Pt 4):835-845.
7. Tsuboi Y., Dickson D.W. Dementia with Lewy bodies and Parkinson's disease with dementia: are they different?. Parkinsonism Relat Disord 2005 Jun, 11(Suppl. 1):S47-51.
8. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004 Mar, 55(3):306-319.
9. Brooks D.J. Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography. Mov Disord 2009, 24(Suppl. 2):S742-S747.
10. Gomperts S.N., Rentz D.M., Moran E., Becker J.A., Locascio J.J., Klunk W.E., et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008 Sep 16, 71(12):903-910.
11. Edison P., Rowe C.C., Rinne J.O., Ng S., Ahmed I., Kemppainen N., et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatr 2008 Dec, 79(12):1331-1338.
12. Minoshima S., Foster N.L., Sima A.A., Frey K.A., Albin R.L., Kuhl D.E. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001 Sep, 50(3):358-365.
13. Lim S.M., Katsifis A., Villemagne V.L., Best R., Jones G., Saling M., et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 2009 Oct, 50(10):1638-1645.
14. Yong S.W., Yoon J.K., An Y.S., Lee P.H. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy Bodies. Eur J Neurol 2007 Dec, 14(12):1357-1362.
15. Kwon K.Y., Choi C.G., Kim J.S., Lee M.C., Chung S.J. Comparison of brain MRI and 18F-FDG PET in the differential diagnosis of multiple system atrophy from Parkinson's disease. Mov Disord 2007 Dec, 22(16):2352-2358.
16. Eckert T., Barnes A., Dhawan V., Frucht S., Gordon M.F., Feigin A.S., et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005 Jul 1, 26(3):912-921.
17. Lowe V.J., Kemp B.J., Jack C.R., Senjem M., Weigand S., Shiung M., et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 2009 Jun, 50(6):878-886.
18. Sateia M. International classification of sleep disorders: diagnostic and coding manual 2005, American Academy of Sleep Medicine, Westchester, IL.
19. Kokmen E., Smith G.E., Petersen R.C., Tangalos E., Ivnik R.C. The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol 1991 Jul, 48(7):725-728.
20. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, D.C. 4th ed.
21. Low P.A. Laboratory evaluation of autonomic function. Suppl Clin Neurophysiol 2004, 57:358-368.
22. Iranzo A., Molinuevo J.L., Santamaria J., Serradell M., Marti M.J., Valldeoriola F., et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006 Jul, 5(7):572-577.
23. Yamanaka Y., Asahina M., Hiraga A., Sakakibara R., Oka H., Hattori T. Over 10 years of isolated autonomic failure preceding dementia and parkinsonism in 2 patients with Lewy body disease. Mov Disord 2007 Mar 15, 22(4):595-597.
24. Brooks D.J. The role of structural and functional imaging in parkinsonian states with a description of PET technology. Semin Neurol 2008 Sep, 28(4):435-445.
25. Bohnen N.I., Muller M.L., Koeppe R.A., Studenski S.A., Kilbourn M.A., Frey K.A., et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009 Nov 17, 73(20):1670-1676.
26. Kuhl D.E., Minoshima S., Fessler J.A., Frey K.A., Foster N.L., Ficaro E.P., et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996 Sep, 40(3):399-410.
27. Dickson D.W. Dementia with Lewy bodies: neuropathology. Journal of geriatric psychiatry and neurology. Winter 2002, 15(4):210-216.
28. Burack M.A., Hartlein J., Flores H.P., Taylor-Reinwald L., Perlmutter J.S., Cairns N.J. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010 Jan 5, 74(1):77-84.
29. Kazmierczak A., Strosznajder J.B., Adamczyk A. alpha-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells. Neurochem Int 2008 Dec, 53(6-8):263-269.
30. Kikuchi A., Takeda A., Okamura N., Tashiro M., Hasegawa T., Furumoto S., et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 2010 Jun, 133(Pt 6):1772-1778.